ALK202 Plus Other Drugs for Advanced Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination cancer medicine (ALK202) for non-small cell lung cancer that hasn't responded to standard treatments. The goal is to see if this drug combination shrinks tumors and is safe to take.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You have non-small cell lung cancer with at least one measurable tumor on imaging
- You can provide a tumor sample (fresh or old tissue) for genetic testing, or get sponsor approval to skip this
- You are expected to live at least 3 months
- You have not had recent cancer treatments (chemotherapy, immunotherapy, or targeted therapy within 2–6 weeks depending on the drug)
- You have not taken certain medications that interact with ALK202 in the past 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ALK201 combined with another drug (ivonescimab) to see if they are safe and help people with a type of lung cancer called squamous non-small cell lung cancer. If you join, you may receive the combination treatment and be closely monitored.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.